ClinicalTrials.gg
RecruitingNCT05029063TRIM-LineUpdated Jul 9, 2025

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

A Phase 3 interventional study of Rivaroxaban 10 MG in Venous Thromboembolism and Cancer, sponsored by Ottawa Hospital Research Institute. Recruiting at 11 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Ottawa Hospital Research Institute · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,828
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 61 studies testing rivaroxaban in Venous Thromboembolism — 18 open to participants now, 18 under way, 6 of them phase 3. Rivaroxaban · Venous Thromboembolism.

Planned enrollment
11th of 61
1,828 · median 272
Started
2022
with 1 other
Phase 3
26 of 61
5 open now
Primary completion
2026-12
later than 7 of 17 live
Registered
42nd of 61
by date
Lead sponsor
4 of 61
Ottawa Hospital Research Institute

Among the 61 studies testing rivaroxaban in Venous Thromboembolism, this one is the 11th largest by planned enrollment, is one of 2 that started in 2022, is one of 26 in phase 3, reaches primary completion later than 7 of the 17 other live ones, and was the 42nd registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

18 of the 61 studies testing rivaroxaban in Venous Thromboembolism are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing rivaroxaban in Venous Thromboembolism, or all of them as a file.
02

Study summary

The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.

Read the detailed description

TRIM-Line is a double blind randomized controlled trial comparing rivaroxaban 10mg po daily vs placebo in patients with active cancer and indwelling CVC. This will involve 9 centers across Canada.

03

Conditions studied

  • Venous Thromboembolism
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years of age or older with a new or existing diagnosis of cancer and a CVC inserted in the last 72 hours.

Exclusion criteria

Exclusion criteria:

  1. CVC in place for >72 hours
  2. Patient requires anticoagulation for other indications
  3. Concomitant use of dual antiplatelet therapy
  4. Major bleeding event in the last 4 weeks
  5. Patients receiving concomitant systemic treatment with strong inhibitors of both CYP 3A4 and P-gp (such as cobicistat, ketoconazole, itraconazole, posaconazole, or ritonavir).
  6. Known pregnancy or plan to become pregnant in next 3 months
  7. Severe renal insufficiency ( \<30 mL/min (defined by Cockcroft-Gault) in the previous 3 months
  8. Documented severe liver disease (e.g., acute clinical hepatitis, chronic active hepatitis or cirrhosis) in the previous 3 months
  9. Known thrombocytopenia ( count \< 50x 109/L) in the previous 3 months
  10. Known allergy to rivaroxaban
  11. \<3 months
  12. History of condition at increased bleeding risk including, but not limited to:

    1. cerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with recent bleeding, spontaneous or acquired impairment of hemostasis in the past 4 weeks.
    2. Chronic hemorrhagic disorder
  13. Primary diagnosis of basal cell or squamous cell carcinoma of the skin only
  14. Refused or unable to obtain consent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,828 participants (estimated)

Study arms

  • Experimental
    Experimental

    Rivaroxaban 10mg OD

    Drug: Rivaroxaban 10 MG

  • Placebo comparator
    Control

    Identical Placebo 10mg OD

    Drug: Rivaroxaban 10 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Major VTE prevention

    Number of Major VTE's in patient population

    Time frame: 90 days (± 3 days) of randomization

  2. Episodes of Major Bleeding

    Number of participants who had a major bleed

    Time frame: 90 days (± 3 days) of randomization

Secondary outcomes

  1. Number of participants with Clinically Relevant Non-Major Bleeding (CRNMB)

    As defined by ISTH

    Time frame: 90 days (± 3 days) of randomization

  2. Number of patients who had a fatal VTE

    Fatal VTE

    Time frame: 90 days (± 3 days) of randomization

  3. Number of patients who benefitted from using the experimental intervention

    Composite of major VTE and major bleeding

    Time frame: 90 days (± 3 days) of randomization

  4. PE

    Incidental and Symptomatic

    Time frame: 90 days (± 3 days) of randomization

  5. Proximal CVC VTE

    Incidental and symptomatic proximal (axillary vein or more proximal) upper extremity CVC-related DVT

    Time frame: 90 days (± 3 days) of randomization

  6. Distal CVC VTE

    Incidental and symptomatic distal (brachial vein) or proximal (axillary vein or more proximal) upper extremity CVC-related DVT

    Time frame: 90 days (± 3 days) of randomization

  7. Proximal Lower extremity DVT

    Incidental and symptomatic proximal (popliteal vein or more proximal) lower extremity DVT

    Time frame: 90 days (± 3 days) of randomization

  8. Distal Lower extremity DVT

    Incidental and symptomatic distal or proximal (popliteal vein or more proximal) lower extremity DVT

    Time frame: 90 days (± 3 days) of randomization

  9. Number of participants with Unusual site thrombosis including: splanchnic vein (portal, splenic, superior mesenteric, inferior mesenteric, hepatic) cerebral vein, renal or gonadal vein thromboses

    Unusual site thrombosis including: splanchnic vein (portal, splenic, superior mesenteric, inferior mesenteric, hepatic) cerebral vein, renal or gonadal vein thromboses

    Time frame: 90 days (± 3 days) of randomization

  10. Number of participants with Superficial upper or lower extremity vein thrombosis

    Superficial upper or lower extremity vein thrombosis

    Time frame: 90 days (± 3 days) of randomization

  11. Number of participants with an arterial thromboembolic event including: MI, stroke, peripheral arterial disease

    Arterial thromboembolic events defined as a diagnostically confirmed final clinical diagnosis of myocardial infarction, stroke or peripheral arterial disease involving the following arterial vascular beds: carotid, upper or lower extremity, gastrointestinal tract, liver, spleen, or kidney

    Time frame: 90 days (± 3 days) of randomization

  12. CVC Life-span

    Life span of inserted CVC

    Time frame: 90 days (± 3 days) of randomization

  13. Number of patients with CVC occlusion occurring after the start of therapy, defined as an obstruction of the CVC lumen that prevents or limits the ability to flush, withdraw blood and/or administer solutions or medications.

    CVC occlusion occurring after the start of therapy, defined as an obstruction of the CVC lumen that prevents or limits the ability to flush, withdraw blood and/or administer solutions or medications.

    Time frame: 90 days (± 3 days) of randomization

  14. Number of patients with CVC-related blood stream infection defined as the presence of bacteremia originating from the CVC according to the definition from the Centers for Disease Control and Prevention

    CVC-related blood stream infection defined as the presence of bacteremia originating from the CVC according to the definition from the Centers for Disease Control and Prevention

    Time frame: 90 days (± 3 days) of randomization

  15. Number of participants who passed away during the trial

    Overall mortality

    Time frame: 90 days (± 3 days) of randomization

  16. EQ-5D-5L Health-related quality of life

    Health-related quality of life

    Time frame: 90 days (± 3 days) of randomization

  17. ICER

    Incremental cost-effectiveness ratio (ICER) at one year

    Time frame: 1 Year

07

Study locations

11 of 11 sites recruiting
08

References and documents

Publications

  • Ikesaka R, Siegal D, Mallick R, Wang TF, Witham D, Webb C, Carrier M; Canadian Venous Thromboembolism Research Network (CanVECTOR). Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial. Res Pract Thromb Haemost. 2021 May 5;5(4):e12517. doi: 10.1002/rth2.12517. eCollection 2021 May. PubMed 34027291 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.

Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2021
First posted
Aug 31, 2021
StartActual
Oct 5, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05029063
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Oct 5, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 9, 2025

Study contacts

Bashour Yazji
Contact
byazji@ohri.ca
613-737-8899 ext. 73958
Dr. Marc Carrier
principal investigator · Ottawa Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion